02.04.19

EyePoint Pharmaceuticals Announces US Commercial Launch of Yutiq

Source: EyePoint Pharmaceuticals

01.28.19

EyePoint Pharmaceuticals Appoints David Guyer, MD, to Board of Directors

Source: EyePoint Pharmaceuticals

01.03.19

EyePoint Pharmaceuticals to Launch Dexycu and Yutiq in First Quarter of 2019

Source: EyePoint Pharmaceuticals

12.17.18

EyePoint Pharmaceuticals Added to NASDAQ

Source: EyePoint Pharmaceuticals

11.27.18

EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary

Source: EyePoint Pharmaceuticals

11.12.18

EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for Dexycu by CMS

Source: EyePoint Pharmaceuticals

10.29.18

EyePoint Pharmaceuticals Presents Positive Yutiq 24-month Follow-up Data at AAO

Source: EyePoint Pharmaceuticals

10.18.18

EyePoint Pharmaceuticals Announces Data Highlighting Yutiq to be Presented at the AAO 2018 Annual Meeting

Source: EyePoint Pharmaceuticals

10.15.18

EyePoint Pharmaceuticals Receives FDA Approval of Yutiq for Chronic Noninfectious Uveitis

Source: EyePoint Pharmaceuticals

10.01.18

EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants

Source: EyePoint Pharmaceuticals

View more stories